Post-market Clinical Follow-up Study on the Performance and Safety of a Vent Catheter Used During Cardiopulmonary Bypass.
Prior to the implementation of the Medical Device Regulation (MDR), the clinical evaluation of existing devices was conducted by Notified Bodies (NBs) based on clinical data obtained from equivalent devices, and CE certificates were issued for devices exhibiting similar characteristics. Following the transition to the MDR, the European Commission's Guidance Document MEDDEV 2.12/2 highlighted that Notified Bodies, which issued CE certificates under the previous regime, must now organize Post-Marketing Clinical Follow-up (PMCF) studies to verify the performance and safety of the device in accordance with its intended use throughout its lifecycle. Consequently, PMCF studies are being planned to demonstrate that medical devices previously marked with the CE mark under the old regulations are used safely for patients throughout their lifecycle.
Primary Objective To demonstrate the performance of the Bıçakcılar Vent Catheter in patients for whom its use is planned, in accordance with the device's intended purpose as outlined in the user manual, taking into account the following aspects: bleeding, trauma, passage manipulation, insertion and removal, compliance with the intended use, occlusion, retention of debris, effective use, and maintenance of its form
調査の概要
詳細な説明
Primary Endpoints The primary endpoints have been designed to encompass all clinical outcomes that characterize the device's performance. The evaluation items listed below, which are directly related to the Bıçakcılar Vent Catheter, will be measured using a Likert scale with values ranging from 1 to 5.
- Presence of bleeding
- Impact of trauma
- Manipulation during insertion
- Placement
- Removal (including removal of the stylet, if applicable)
- Conformity to intended use/Drainage capability
- Blockage formation in the ports
- Presence of residue
- Effective use
- Retention of shape
Secondary Endpoints Since factors such as the surgeon performing the operation, the perfusionist operating the heart-lung machine, and the patients' clinical characteristics may act as confounding variables, other variables affecting the primary endpoints will be identified through secondary endpoints.
- General and demographic information
- Concomitant diseases
- Concomitant treatments
- Biochemical findings
- Echocardiographic findings
- Total duration of the procedure
- Type of procedure
- Vital and cardiac assessments
- Evaluations related to the Vent catheter
- Perfusion evaluations
- Cardioplegia evaluations
- Data on adverse events and complications
Definition of Participants (Volunteers) / Study Population Patients for whom a decision has been made by their physician to undergo routine surgical procedures using cardiopulmonary bypass, and for whom the use of a vent catheter is planned during the procedure
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Gizem Özdemir, Biomedical Engineer
- 電話番号：+90 5346137760
- メール：gizemozdemir@kocyasa.com
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
- Patients with diseased or abnormal tissue at the catheter insertion site
- Patients with intracardiac and/or major intravascular thrombi and/or masses
- Patients with left atrial/ventricular myxoma
- Patients who have difficulty understanding or complying with the study
- Patients who may present a conflict of interest (e.g., relatives of employees of the sponsoring company)
- Patients who have participated in any clinical trial within the past 30 days
説明
Inclusion Criteria:
Patients who have consulted the Department of Cardiovascular Surgery and for whom the physician has decided to perform heart surgery using the cardiopulmonary bypass technique,
- Patients for whom the use of a vent catheter is planned during surgery
- Patients who, in the "Use of Patient Data for Educational and Research Purposes" section of the Department of Cardiovascular Surgery Informed Consent Form, have given permission for their data to be used
Exclusion Criteria:
• Patients with diseased or abnormal tissue in the catheter placement site
- Patients with intracardiac and/or major intravascular thrombi and/or masses
- Patients with left atrial/ventricular myxoma
- Patients who have difficulty understanding or complying with the study
- Patients who may pose a conflict of interest (e.g., relatives of employees of the sponsoring company)
- Patients who have participated in any clinical trial within the past 30 days
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Trauma effects
時間枠：It will be measured during the surgery up to 6 hours.
|
Primary endpoints are structured to encompass all clinical use outcomes characterizing device performance.
Evaluation items directly related to the Bıçakcılar Vent Catheter will be measured using a Likert scale with values ranging from 1 to 5.
|
It will be measured during the surgery up to 6 hours.
|
|
Presence of bleeding
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used the 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Manipulation during insertion
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Catheter placement
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used the 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Catheter removal
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used the 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Removal of the stylet (If the catheter contains a stylet)
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used the 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Suitability of the device for its intended use / emptying capability
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Blockage in the holes during emptying
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Was there any residue left on the catheter surface after the removal procedure was completed?
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Was its use as a filler for air extraction effective?
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
|
Has the device retained its pre-operation form? (Evaluate for deformation, bending, or fractures)
時間枠：It will be measured during the surgery up to 6 hours.
|
It will be used 5-likert scale.
|
It will be measured during the surgery up to 6 hours.
|
協力者と研究者
捜査官
- 主任研究者：Atıf Akçevin, Prof. Dr.、Koc University Hospital
- スタディディレクター：Ozan Onur Balkanay, Prof. Dr.、İstanbul University-Cerrahpaşa Prof. Dr. Murat Dilmener Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CIP-33003
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。